A 2-stage Genome-wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2012 Oct 2

PMID 23021708

Citations 31

Authors

Sarah L Kerns

Richard Stock

Nelson Stone

Michael Buckstein

Yongzhao Shao

Christopher Campbell

Lynda Rath

Dirk De Ruysscher

Guido Lammering

Rosetta Hixson

Jamie Cesaretti

Mitchell Terk

Harry Ostrer

Barry S Rosenstein

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify single nucleotide polymorphisms (SNPs) associated with development of erectile dysfunction (ED) among prostate cancer patients treated with radiation therapy.

Methods And Materials: A 2-stage genome-wide association study was performed. Patients were split randomly into a stage I discovery cohort (132 cases, 103 controls) and a stage II replication cohort (128 cases, 102 controls). The discovery cohort was genotyped using Affymetrix 6.0 genome-wide arrays. The 940 top ranking SNPs selected from the discovery cohort were genotyped in the replication cohort using Illumina iSelect custom SNP arrays.

Results: Twelve SNPs identified in the discovery cohort and validated in the replication cohort were associated with development of ED following radiation therapy (Fisher combined P values 2.1×10(-5) to 6.2×10(-4)). Notably, these 12 SNPs lie in or near genes involved in erectile function or other normal cellular functions (adhesion and signaling) rather than DNA damage repair. In a multivariable model including nongenetic risk factors, the odds ratios for these SNPs ranged from 1.6 to 5.6 in the pooled cohort. There was a striking relationship between the cumulative number of SNP risk alleles an individual possessed and ED status (Sommers' D P value=1.7×10(-29)). A 1-allele increase in cumulative SNP score increased the odds for developing ED by a factor of 2.2 (P value=2.1×10(-19)). The cumulative SNP score model had a sensitivity of 84% and specificity of 75% for prediction of developing ED at the radiation therapy planning stage.

Conclusions: This genome-wide association study identified a set of SNPs that are associated with development of ED following radiation therapy. These candidate genetic predictors warrant more definitive validation in an independent cohort.

Citing Articles

Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.

Nuijens A, Oei A, Franken N, Rasch C, Stalpers L Curr Oncol. 2025; 32(1).

PMID: 39851963 PMC: 11763857. DOI: 10.3390/curroncol32010047.

Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.

Elbanna M, Chowdhury N, Rhome R, Fishel M Front Oncol. 2021; 11:749496.

PMID: 34733787 PMC: 8558533. DOI: 10.3389/fonc.2021.749496.

Low dose ionizing radiation effects on the immune system.

Lumniczky K, Impens N, Armengol G, Candeias S, Georgakilas A, Hornhardt S Environ Int. 2020; 149:106212.

PMID: 33293042 PMC: 8784945. DOI: 10.1016/j.envint.2020.106212.

Harnessing genome-wide association studies to minimize adverse radiation-induced side effects.

Benitez C, Knox S Radiat Oncol J. 2020; 38(4):226-235.

PMID: 33233031 PMC: 7785837. DOI: 10.3857/roj.2020.00556.

Genetically-regulated transcriptomics & copy number variation of proctitis points to altered mitochondrial and DNA repair mechanisms in individuals of European ancestry.

Pathak G, Polimanti R, Silzer T, Wendt F, Chakraborty R, Phillips N BMC Cancer. 2020; 20(1):954.

PMID: 33008348 PMC: 7530964. DOI: 10.1186/s12885-020-07457-1.

References

Merrick G, Butler W, Wallner K, Galbreath R, Anderson R, Kurko B . Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 62(2):437-47. DOI: 10.1016/j.ijrobp.2004.10.001. View

Witte S, Villalba M, Bi K, Liu Y, Isakov N, Altman A . Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem. 2000; 275(3):1902-9. DOI: 10.1074/jbc.275.3.1902. View

Grimm P, Billiet I, Bostwick D, Dicker A, Frank S, Immerzeel J . Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012; 109 Suppl 1:22-9. DOI: 10.1111/j.1464-410X.2011.10827.x. View

Stock R, Stone N, Cesaretti J, Rosenstein B . Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2005; 64(2):527-33. DOI: 10.1016/j.ijrobp.2005.07.981. View

Zagar T, Stock R, Cesaretti J, Stone N . Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy. 2007; 6(1):26-33. DOI: 10.1016/j.brachy.2006.11.003. View

Potters L, Torre T, Fearn P, Leibel S, Kattan M . Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001; 50(5):1235-42. DOI: 10.1016/s0360-3016(01)01578-4. View

Snyder K, Stock R, Buckstein M, Stone N . Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012; 110(2):221-5. DOI: 10.1111/j.1464-410X.2011.10800.x. View

Ziera T, Irlbacher H, Fromm A, Latouche C, Krug S, Fromm M . Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB J. 2009; 23(11):3936-46. DOI: 10.1096/fj.09-134759. View

Wheat J, Hedgepeth R, He C, Zhang L, Wood Jr D . Clinical interpretation of the Expanded Prostate Cancer Index Composite-Short Form sexual summary score. J Urol. 2009; 182(6):2844-9. DOI: 10.1016/j.juro.2009.08.088. View

10.

Panagiotou O, Ioannidis J . What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol. 2012; 41(1):273-86. DOI: 10.1093/ije/dyr178. View

11.

Talcott J, Manola J, Clark J, Kaplan I, Beard C, Mitchell S . Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003; 21(21):3979-86. DOI: 10.1200/JCO.2003.01.199. View

12.

. The International HapMap Project. Nature. 2003; 426(6968):789-96. DOI: 10.1038/nature02168. View

13.

Brown T, Yang T, Zaitsevskaia T, Xia Y, Dunn C, Sigle R . Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. J Biol Chem. 2004; 279(15):14772-83. DOI: 10.1074/jbc.M309678200. View

14.

Rosenstein B . Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics. 2011; 12(2):267-75. PMC: 3128821. DOI: 10.2217/pgs.10.186. View

15.

Robinson J, Moritz S, Fung T . Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002; 54(4):1063-8. DOI: 10.1016/s0360-3016(02)03030-4. View

16.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

17.

Wu L, Einstein M, Geissler W, Chan H, Elliston K, Andersson S . Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem. 1993; 268(17):12964-9. View

18.

Kerns S, Ostrer H, Stock R, Li W, Moore J, Pearlman A . Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 78(5):1292-300. PMC: 2991431. DOI: 10.1016/j.ijrobp.2010.07.036. View

19.

Alemozaffar M, Regan M, Cooperberg M, Wei J, Michalski J, Sandler H . Prediction of erectile function following treatment for prostate cancer. JAMA. 2011; 306(11):1205-14. PMC: 3831607. DOI: 10.1001/jama.2011.1333. View

20.

Rosen R, Cappelleri J, Smith M, Lipsky J, Pena B . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 2000; 11(6):319-26. DOI: 10.1038/sj.ijir.3900472. View